DEC 1 0 2001 5

## PATENT APPLICATION Atty. Docket No. 28110/36120B

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chadwick et al.	)	I hereby certify that this paper is being
••	)	deposited with the United States Postal
Serial No: 09/905,732	)	Service as First Class Mail, postage
	)	prepaid in an envelope addressed to:
Filed: July 13, 2001	)	Commissioner for Patents, Washington,
•	)	D.C. 20231, on this date:
For: Methods and Compositions Relating	)	
to CD39-Like Polypeptides and Nucleic	)	October 23, 2001
Acids	)	$\mathcal{O}$
	)	1 licole Summerston
Group Art Unit: 1644	)	Nicole Burmeister
	)	RECEIVED
Examiner: A. DeCloux	)	NECEIVED

## INFORMATION DISCLOSURE STATEMENT

DEC 1 1 2001

TECH CENTER 1600/2900

Commissioner for Patents Washington, DC 20231

Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, the attached form PTO-1449 is hereby submitted by Applicants for consideration in connection with the above-identified patent application. Pursuant to 37 C.F.R. § 1.98(d), Applicants are not submitting copies of the listed documents because they were previously submitted to the Patent Office in an earlier application, U.S.S.N. 09/240,639, which is identified in the attached form PTO-1449 and is relied on for an earlier effective filing date under 35 U.S.C. § 120. The information disclosure statement submitted in this earlier application complies with 37 C.F.R. § 1.98(a)-(c). Copies of any listed documents will be resubmitted at the Examiner's request.

Enclosed is a copy of the International Search Report in an application owned by the assignee of this application, Hyseq, Inc. (International Application Number PCT/US99/16180, filed July 16, 1999).

This Information Disclosure Statement is not intended to be an admission that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. § 102 or § 103.

Because this Information Disclosure Statement is being submitted before the mailing of a first office action on the merits under 37 C.F.R. § 1.97(b)(2), no fees are thought to be due. However, should any fees be deemed due, please charge any such fees to Marshall, Gerstein & Borun's Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By:

Michael F. Borun

Registration No. 25,447 6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6402

(312) 474-6300

October 23, 2001